MEREO BIOPHARMA GROUP PLC Depreciation
MEREO BIOPHARMA GROUP PLC (MREO) reported Depreciation of $82.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC depreciation for the quarter ending 2026-06-30 was $38.00K, a 13.64% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC depreciation for the quarter ending 2026-03-31 was $44.00K, a 15.79% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC depreciation for the quarter ending 2025-12-31 was $36.00K, a 5.26% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC depreciation for the quarter ending 2025-09-30 was $39.00K, a 61.00% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC depreciation for fiscal 2025 was $157.00K, a 9.79% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC depreciation for fiscal 2024 was $143.00K, a 16.37% decline from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC depreciation for fiscal 2023 was $171.00K, a 5.52% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC depreciation for fiscal 2022 was $181.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $82.00K 10-Q · filed 2026-08-11 | $118.00K derived: sum of 3 quarters · filed 2026-08-11 | $157.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-12 | $80.00K derived: sum of 2 quarters · filed 2026-05-12 | $119.00K derived: sum of 3 quarters · filed 2026-05-12 | $163.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $75.00K derived: sum of 2 quarters · filed 2026-03-19 | $119.00K derived: sum of 3 quarters · filed 2026-08-11 | $157.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $83.00K derived: sum of 2 quarters · filed 2026-08-11 | $121.00K 10-Q · filed 2025-11-10 | $159.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $82.00K 10-Q · filed 2026-08-11 | $120.00K derived: sum of 3 quarters · filed 2026-08-11 | $220.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $38.00K 10-Q · filed 2026-05-12 | $76.00K derived: sum of 2 quarters · filed 2026-05-12 | $176.00K derived: sum of 3 quarters · filed 2026-05-12 | $276.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $138.00K derived: sum of 2 quarters · filed 2026-03-19 | $238.00K derived: sum of 3 quarters · filed 2026-03-19 | $143.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-12 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $105.00K 10-Q · filed 2025-11-10 | $283.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-13 | $64.00K 10-Q · filed 2025-08-12 | $183.00K derived: sum of 3 quarters · filed 2025-05-13 | $283.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $41.00K 10-Q · filed 2025-05-13 | $83.00K derived: sum of 2 quarters · filed 2025-05-13 | $183.00K derived: sum of 3 quarters · filed 2025-05-13 | $283.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $142.00K derived: sum of 2 quarters · filed 2025-03-26 | $242.00K derived: sum of 3 quarters · filed 2025-03-26 | $171.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-12 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $129.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-13 | $82.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $42.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $181.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |